Pacira BioSciences, Inc. (PCRX)
Quick ratio
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | US$ in thousands | 276,774 | 245,965 | 247,053 | 184,052 | 153,298 | 99,119 | 86,810 | 35,545 | 104,139 | 109,424 | 122,061 | 226,751 | 585,578 | 134,036 | 105,774 | 66,699 | 99,957 | 125,244 | 78,552 | 54,589 |
| Short-term investments | US$ in thousands | 207,841 | 207,845 | 157,173 | 141,838 | 125,283 | 136,069 | 133,956 | 138,454 | 184,512 | 219,301 | 194,332 | 225,443 | 70,831 | 559,822 | 540,821 | 523,364 | 421,705 | 406,881 | 248,240 | 263,875 |
| Receivables | US$ in thousands | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Total current liabilities | US$ in thousands | 309,920 | 306,401 | 92,690 | 93,444 | 97,383 | 93,661 | 108,912 | 98,698 | 147,774 | 131,526 | 133,179 | 305,073 | 521,118 | 225,788 | 228,693 | 232,084 | 253,328 | 86,272 | 70,583 | 80,313 |
| Quick ratio | 1.56 | 1.48 | 4.36 | 3.49 | 2.86 | 2.51 | 2.03 | 1.76 | 1.95 | 2.50 | 2.38 | 1.48 | 1.26 | 3.07 | 2.83 | 2.54 | 2.06 | 6.17 | 4.63 | 3.97 |
December 31, 2024 calculation
Quick ratio = (Cash + Short-term investments + Receivables) ÷ Total current liabilities
= ($276,774K
+ $207,841K
+ $—K)
÷ $309,920K
= 1.56
The quick ratio of Pacira BioSciences, Inc. has shown fluctuation over the periods presented in the data. The quick ratio measures the company's ability to meet its short-term obligations with its most liquid assets.
The quick ratio ranged from a high of 6.17 on September 30, 2020, indicating a strong ability to cover short-term liabilities with liquid assets, to a low of 1.26 on December 31, 2021, signaling a potential liquidity risk as the ratio fell below 1, implying that current liabilities may not be fully covered by quick assets.
Subsequently, the quick ratio improved and ranged between 1.48 to 4.36 in the following periods, reflecting an enhanced ability to cover short-term obligations with liquid assets.
Overall, monitoring the quick ratio can provide insights into Pacira BioSciences' liquidity position and its ability to manage short-term financial obligations effectively.
Peer comparison
Dec 31, 2024